Inactive Instrument
Checkmate Pharmaceuticals, Inc. Stock
Stocks
CMPI
US1628181083
Biotechnology & Medical Research
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 12/12/2018 | |
Robert Landry
DFI | Director of Finance/CFO | 62 | 31/05/2022 |
James Wooldridge
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/10/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Nouhad Husseini
BRD | Director/Board Member | - | 31/05/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 31/5/22 | Issuer sale | Director | 36,778 | 0.1700% | ||
| 31/5/22 | Issuer sale | Chief Financial Officer | 278,480 | 1.2874% | ||
| 31/5/22 | Issuer sale | Chief Executive Officer | 279,437 | 1.2919% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +0.38% | - | - | 231M | |
| -1.90% | +11.59% | +62.29% | +102.60% | 71.56B | |
| -3.21% | -4.32% | +31.19% | +59.75% | 54.43B | |
| -2.45% | -5.85% | -3.39% | +453.48% | 27.59B | |
| -1.27% | +9.09% | +46.56% | +4.13% | 23.91B | |
| +0.41% | -1.46% | -18.10% | -14.09% | 23.14B | |
| +0.10% | +1.40% | +38.98% | -20.04% | 18.65B | |
| +3.81% | +16.28% | +270.78% | +488.06% | 18.64B | |
| -0.95% | +2.46% | +24.40% | +574.22% | 16.01B | |
| +0.67% | -5.88% | +32.28% | +136.59% | 12.54B | |
| Average | -0.49% | +2.96% | +53.89% | +198.30% | 29.61B | |
| Weighted average by Cap. | -1.25% | +1.72% | +50.01% | +159.52% |
Employees
31
